By Colin Kellaher
Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.
Tonix on Tuesday said it expects the FDA to communicate a target action date and a decision on whether to grant priority review to the application in a so-called "Day 74" letter, which the agency issues within 74 days from its receipt of a submission.
The Chatham, N.J., company said TNX-102 SL, a non-opioid, sublingual pain reliever, has the potential to be the first member of a new class of analgesic drugs for fibromyalgia, adding that an FDA green light would make it the first new drug for treating fibromyalgia in more than 15 years.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 17, 2024 08:30 ET (13:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。